{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:20:19Z","timestamp":1789676419024,"version":"4.0.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":205,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HO 1875\/ 16-1"],"award-info":[{"award-number":["HO 1875\/ 16-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RA 2151\/4-1"],"award-info":[{"award-number":["RA 2151\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HO 1875\/ 16\u20101"],"award-info":[{"award-number":["HO 1875\/ 16\u20101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RA 2151\/4\u20101"],"award-info":[{"award-number":["RA 2151\/4\u20101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Antiresorptive therapy is an important component of a multimodal approach to treating patients with advanced malignancies and metastatic bone disease. Over the past decade, overall survival of affected patients has improved in most cancer entities, and long-term disease control is a realistic goal in many cases. There are emerging clinical studies showing the benefits of an initial antiresorptive therapy using bisphosphonates or denosumab. However, some adverse events of these therapies, such as osteonecrosis of the jaw, correlate with the cumulative doses given, and there is an increasing clinical need for new antiresorptive concepts to treat long-term survivors. This review summarizes the clinical evidence of antiresorptive therapies across different cancers with bone involvement and presents concepts of dose-reduction protocols for long-term survivors with established metastatic bone disease. \u00a9 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4391","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T03:51:38Z","timestamp":1623815498000},"page":"1906-1913","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-4666","authenticated-orcid":false,"given":"Tilman D","family":"Rachner","sequence":"first","affiliation":[{"name":"Center for Healthy Aging Technische Universit\u00e4t Dresden Dresden Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ) Heidelberg Germany"},{"name":"Division of Endocrinology, Diabetes and Bone Diseases & Center for Healthy Ageing, Department of Medicine III Technische Universit\u00e4t Dresden Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism University of Sheffield Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[{"name":"Philips-University of Marburg Marburg Germany"},{"name":"Frankfurt Center of Bone Health Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz C","family":"Hofbauer","sequence":"additional","affiliation":[{"name":"Center for Healthy Aging Technische Universit\u00e4t Dresden Dresden Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ) Heidelberg Germany"},{"name":"Division of Endocrinology, Diabetes and Bone Diseases & Center for Healthy Ageing, Department of Medicine III Technische Universit\u00e4t Dresden Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0001","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol Rev."},{"issue":"12","key":"2024012713460323800_jbmr4391-bib-0002","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol."},{"issue":"2","key":"2024012713460323800_jbmr4391-bib-0003","first-page":"188351","article-title":"Cholesterol and beyond\u2014the role of the mevalonate pathway in cancer biology","volume":"1873","author":"G\u00f6bel","year":"2020","journal-title":"Biochim Biophys Acta."},{"issue":"11","key":"2024012713460323800_jbmr4391-bib-0004","doi-asserted-by":"crossref","first-page":"e1982","DOI":"10.1038\/cddis.2015.332","article-title":"Prospects of adjuvant RANKL inhibition in breast cancer?","volume":"6","author":"Rachner","year":"2015","journal-title":"Cell Death Dis."},{"issue":"2","key":"2024012713460323800_jbmr4391-bib-0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/cancers13020221","article-title":"Current melanoma treatments: where do we stand?","volume":"13","author":"Moreira","year":"2021","journal-title":"Cancer."},{"key":"2024012713460323800_jbmr4391-bib-0006","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"2024012713460323800_jbmr4391-bib-0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-030-20301-6_7","article-title":"Bone metastasis of breast cancer","volume":"1152","author":"Tahara","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"10001","key":"2024012713460323800_jbmr4391-bib-0008","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2015","journal-title":"Lancet."},{"issue":"3","key":"2024012713460323800_jbmr4391-bib-0009","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"2024012713460323800_jbmr4391-bib-0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024012713460323800_jbmr4391-bib-0011","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol."},{"issue":"9","key":"2024012713460323800_jbmr4391-bib-0012","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"issue":"8","key":"2024012713460323800_jbmr4391-bib-0013","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer."},{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0014","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"2024012713460323800_jbmr4391-bib-0015","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"issue":"7","key":"2024012713460323800_jbmr4391-bib-0016","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4\u2009weeks in women with breast cancer metastatic to bone","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA."},{"issue":"6","key":"2024012713460323800_jbmr4391-bib-0018","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00520-020-05355-7","article-title":"Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency","volume":"28","author":"Yang","year":"2020","journal-title":"Support Care Cancer."},{"issue":"5","key":"2024012713460323800_jbmr4391-bib-0019","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/COC.0b013e3182568f7a","article-title":"Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer","volume":"36","author":"Amir","year":"2013","journal-title":"Am J Clin Oncol."},{"issue":"35","key":"2024012713460323800_jbmr4391-bib-0020","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol."},{"issue":"6","key":"2024012713460323800_jbmr4391-bib-0021","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2024012713460323800_jbmr4391-bib-0022","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1349-7006.2008.00803.x","article-title":"Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases","volume":"99","author":"Yonemori","year":"2008","journal-title":"Cancer Sci"},{"key":"2024012713460323800_jbmr4391-bib-0023","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer."},{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers."},{"issue":"11","key":"2024012713460323800_jbmr4391-bib-0025","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol."},{"issue":"10024","key":"2024012713460323800_jbmr4391-bib-0026","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet."},{"issue":"11","key":"2024012713460323800_jbmr4391-bib-0027","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst."},{"issue":"8","key":"2024012713460323800_jbmr4391-bib-0028","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med."},{"issue":"9810","key":"2024012713460323800_jbmr4391-bib-0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet."},{"issue":"9768","key":"2024012713460323800_jbmr4391-bib-0030","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet."},{"issue":"2","key":"2024012713460323800_jbmr4391-bib-0031","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2006.04.014","article-title":"Myeloma bone disease: pathogenetic mechanisms and clinical assessment","volume":"31","author":"Silvestris","year":"2007","journal-title":"Leuk Res."},{"issue":"18","key":"2024012713460323800_jbmr4391-bib-0032","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma\u2013related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol."},{"issue":"9","key":"2024012713460323800_jbmr4391-bib-0033","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol."},{"issue":"9757","key":"2024012713460323800_jbmr4391-bib-0034","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet."},{"issue":"8","key":"2024012713460323800_jbmr4391-bib-0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol."},{"issue":"12","key":"2024012713460323800_jbmr4391-bib-0036","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"20","key":"2024012713460323800_jbmr4391-bib-0037","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1002\/cncr.32357","article-title":"Characteristics of long-term survivors with multiple myeloma: a National Cancer Data Base analysis","volume":"125","author":"Hsieh","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"2024012713460323800_jbmr4391-bib-0038","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol."},{"issue":"8","key":"2024012713460323800_jbmr4391-bib-0039","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J Clin Oncol."},{"issue":"9","key":"2024012713460323800_jbmr4391-bib-0040","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0041","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1038\/bcj.2015.96","article-title":"Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial","volume":"6","author":"Raje","year":"2016","journal-title":"Blood Cancer J."},{"issue":"3","key":"2024012713460323800_jbmr4391-bib-0042","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"16","key":"2024012713460323800_jbmr4391-bib-0043","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol."},{"issue":"12","key":"2024012713460323800_jbmr4391-bib-0044","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer."},{"issue":"5","key":"2024012713460323800_jbmr4391-bib-0045","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer."},{"issue":"3","key":"2024012713460323800_jbmr4391-bib-0046","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer."},{"issue":"12","key":"2024012713460323800_jbmr4391-bib-0047","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol."},{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0048","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer."},{"issue":"10","key":"2024012713460323800_jbmr4391-bib-0049","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1007\/s00520-019-04676-6","article-title":"Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration","volume":"27","author":"Mjelstad","year":"2019","journal-title":"Support Care Cancer."},{"issue":"6","key":"2024012713460323800_jbmr4391-bib-0050","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024012713460323800_jbmr4391-bib-0051","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","article-title":"The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy","volume":"85","author":"Lo","year":"2016","journal-title":"Bone."},{"key":"2024012713460323800_jbmr4391-bib-0052","doi-asserted-by":"crossref","first-page":"100301","DOI":"10.1016\/j.jbo.2020.100301","article-title":"Incidence of atypical femoral fractures in the treatment of bone metastasis: an alert report","volume":"23","author":"Kaku","year":"2020","journal-title":"J Bone Oncol."},{"issue":"5","key":"2024012713460323800_jbmr4391-bib-0053","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11914-019-00525-x","article-title":"The role of lower-limb geometry in the pathophysiology of atypical femoral fracture","volume":"17","author":"Haider","year":"2019","journal-title":"Curr Osteoporos Rep."},{"issue":"13","key":"2024012713460323800_jbmr4391-bib-0054","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2106\/JBJS.J.01199","article-title":"Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates","volume":"93","author":"Puhaindran","year":"2011","journal-title":"J Bone Joint Surg."},{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6236-6","article-title":"Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review","volume":"19","author":"Takahashi","year":"2019","journal-title":"BMC Cancer."},{"issue":"5","key":"2024012713460323800_jbmr4391-bib-0056","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society","volume":"105","author":"van de Laarschot","year":"2020","journal-title":"J Clin Endocrinol Metabol."},{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0057","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metabol."},{"issue":"35","key":"2024012713460323800_jbmr4391-bib-0058","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","article-title":"Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (alliance)","volume":"35","author":"Shapiro","year":"2017","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024012713460323800_jbmr4391-bib-0059","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/13696998.2019.1651122","article-title":"Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States","volume":"23","author":"Stopeck","year":"2020","journal-title":"J Med Econ."},{"issue":"6","key":"2024012713460323800_jbmr4391-bib-0060","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00520-013-1790-y","article-title":"Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases","volume":"21","author":"Koo","year":"2013","journal-title":"Support Care Cancer."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/10\/1906\/56289695\/jbmr4391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/10\/1906\/56289695\/jbmr4391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:07:40Z","timestamp":1710328060000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/10\/1906-1913\/7499822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,6,16]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4391","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4391\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4391\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4391\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4391\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4391\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4391\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4391\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4391\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4391\/v3\/decision1","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2021-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}